Axa’s Nuvation Bio NUVB Stock Holding History

Axa’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-348,800	Closed	-$628K	–	1126
2023 Q2	$628K	Sell	348,800 -22,800	-6%	-$38.8K	﹤0.01%	919
2023 Q1	$617K	Buy	+371,600	New	+$753K	﹤0.01%	938

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Axa's NUVB Position: Q3 2023 in Review

Axa sold out of Nuvation Bio (NUVB) in Q3 2023, closing a stake of 348,800 shares — an estimated $628K sold.

Axa first reported a position in NUVB in Q1 2023 and held it in 2 quarters. The position peaked at $628K in Q2 2023. 125 funds tracked by Wall St. Rank hold NUVB as of Q3 2023.

Axa reported no remaining Nuvation Bio position as of Q3 2023 after selling out during the quarter.
Axa sold 348,800 Nuvation Bio shares in Q3 2023, an estimated $628K.
Axa first reported a position in Nuvation Bio in Q1 2023 and held it in 2 quarters.
Axa's Nuvation Bio position peaked at $628K in Q2 2023.
125 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.